Sculier JP, et al. - In patients with unresectable non-metastatic non-small cell lung cancer (NSCLC), researchers investigate if induction radiochemotherapy followed by consolidation chemotherapy will improve survival in comparison with the same chemotherapy given as induction followed by consolidation concurrent radiochemotherapy. For unresectable stage III NSCLC, concurrent radiochemotherapy is the recommended treatment. Observations reveal no survival difference between induction and consolidation radiochemotherapy. The cisplatin + docetaxel regimen result in good 2-year (44%) and 5-year (~25%) survivals.